Loading…
Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy
Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventri...
Saved in:
Published in: | Journal of nuclear cardiology 2022-04, Vol.29 (2), p.581-589 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23 |
---|---|
cites | cdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23 |
container_end_page | 589 |
container_issue | 2 |
container_start_page | 581 |
container_title | Journal of nuclear cardiology |
container_volume | 29 |
creator | Jones, K.A. Small, A.D. Ray, S. Hamilton, D.J. Martin, W. Robinson, J. Goodfield, N.E.R. Paterson, C.A. |
description | Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function.
In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy.
Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups.
The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF. |
doi_str_mv | 10.1007/s12350-020-02277-z |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1071358123002544</els_id><sourcerecordid>2648552081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</originalsourceid><addsrcrecordid>eNp9UV1rFTEQDaLYWv0DPkjA59V8bDZZEEGKX1AQij6H3GR2b-p2sya7l97-eud2a21f-pDkwJxzZjKHkNecveOM6feFC6lYxcThCK2r6yfkmCspqkYp_hQx07ySyvAj8qKUC8ZYK9v2OTmSQtdGaHNMducuxDQufogB6A7GOUe_DKnPbtru6bR1Bagb3bAvsdAuZZpj-U3LnN0cu-jxTiNNHZ0QobrQZQyQ-xTHnnqX0XxOV9EjHj1kOm8BnfcvybPODQVe3b4n5NeXzz9Pv1VnP75-P_10Vnkl9Fw1IJ2XqgmGeWmCb_QmAPMK6hC00TXjG-U3TIHCmq8lsFBLp1TTQOchCHlCPq6-07K5hOAP_3ODnXK8dHlvk4v2YWWMW9unnTVtKzXXaPD21iCnPwuU2V6kJeM-ihVNbZQSzHBkiZXlcyolQ3fXgTN7yMquWVnMyt5kZa9R9Ob-bHeSf-EgQa6EgqWxh_y_96O2H1YV4F53EVXFYzK4jpjBzzak-Jj8L4UEuTY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2648552081</pqid></control><display><type>article</type><title>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</title><source>Springer Nature</source><creator>Jones, K.A. ; Small, A.D. ; Ray, S. ; Hamilton, D.J. ; Martin, W. ; Robinson, J. ; Goodfield, N.E.R. ; Paterson, C.A.</creator><creatorcontrib>Jones, K.A. ; Small, A.D. ; Ray, S. ; Hamilton, D.J. ; Martin, W. ; Robinson, J. ; Goodfield, N.E.R. ; Paterson, C.A.</creatorcontrib><description>Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function.
In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy.
Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups.
The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.</description><identifier>ISSN: 1071-3581</identifier><identifier>EISSN: 1532-6551</identifier><identifier>DOI: 10.1007/s12350-020-02277-z</identifier><identifier>PMID: 32748278</identifier><language>eng</language><publisher>Cham: Elsevier Inc</publisher><subject>Breast cancer ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - drug therapy ; Cancer therapies ; Cardiology ; Cardiotoxicity ; diagnostic and prognostic application ; dyssynchrony ; Ejection fraction ; Entropy ; Female ; Heart Diseases ; Humans ; image analysis ; Imaging ; Medical diagnosis ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Original ; Original Article ; Radiology ; Radionuclide Ventriculography ; Retrospective Studies ; Risk Assessment ; RNA: planar ; Stroke Volume ; Ventricular Dysfunction, Left - chemically induced ; Ventricular Dysfunction, Left - diagnostic imaging ; Ventricular Function, Left</subject><ispartof>Journal of nuclear cardiology, 2022-04, Vol.29 (2), p.581-589</ispartof><rights>2022 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology</rights><rights>The Author(s) 2020</rights><rights>2020. The Author(s).</rights><rights>The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</citedby><cites>FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</cites><orcidid>0000-0001-9109-4812</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32748278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, K.A.</creatorcontrib><creatorcontrib>Small, A.D.</creatorcontrib><creatorcontrib>Ray, S.</creatorcontrib><creatorcontrib>Hamilton, D.J.</creatorcontrib><creatorcontrib>Martin, W.</creatorcontrib><creatorcontrib>Robinson, J.</creatorcontrib><creatorcontrib>Goodfield, N.E.R.</creatorcontrib><creatorcontrib>Paterson, C.A.</creatorcontrib><title>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</title><title>Journal of nuclear cardiology</title><addtitle>J. Nucl. Cardiol</addtitle><addtitle>J Nucl Cardiol</addtitle><description>Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function.
In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy.
Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups.
The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.</description><subject>Breast cancer</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Cancer therapies</subject><subject>Cardiology</subject><subject>Cardiotoxicity</subject><subject>diagnostic and prognostic application</subject><subject>dyssynchrony</subject><subject>Ejection fraction</subject><subject>Entropy</subject><subject>Female</subject><subject>Heart Diseases</subject><subject>Humans</subject><subject>image analysis</subject><subject>Imaging</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Original</subject><subject>Original Article</subject><subject>Radiology</subject><subject>Radionuclide Ventriculography</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>RNA: planar</subject><subject>Stroke Volume</subject><subject>Ventricular Dysfunction, Left - chemically induced</subject><subject>Ventricular Dysfunction, Left - diagnostic imaging</subject><subject>Ventricular Function, Left</subject><issn>1071-3581</issn><issn>1532-6551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UV1rFTEQDaLYWv0DPkjA59V8bDZZEEGKX1AQij6H3GR2b-p2sya7l97-eud2a21f-pDkwJxzZjKHkNecveOM6feFC6lYxcThCK2r6yfkmCspqkYp_hQx07ySyvAj8qKUC8ZYK9v2OTmSQtdGaHNMducuxDQufogB6A7GOUe_DKnPbtru6bR1Bagb3bAvsdAuZZpj-U3LnN0cu-jxTiNNHZ0QobrQZQyQ-xTHnnqX0XxOV9EjHj1kOm8BnfcvybPODQVe3b4n5NeXzz9Pv1VnP75-P_10Vnkl9Fw1IJ2XqgmGeWmCb_QmAPMK6hC00TXjG-U3TIHCmq8lsFBLp1TTQOchCHlCPq6-07K5hOAP_3ODnXK8dHlvk4v2YWWMW9unnTVtKzXXaPD21iCnPwuU2V6kJeM-ihVNbZQSzHBkiZXlcyolQ3fXgTN7yMquWVnMyt5kZa9R9Ob-bHeSf-EgQa6EgqWxh_y_96O2H1YV4F53EVXFYzK4jpjBzzak-Jj8L4UEuTY</recordid><startdate>20220401</startdate><enddate>20220401</enddate><creator>Jones, K.A.</creator><creator>Small, A.D.</creator><creator>Ray, S.</creator><creator>Hamilton, D.J.</creator><creator>Martin, W.</creator><creator>Robinson, J.</creator><creator>Goodfield, N.E.R.</creator><creator>Paterson, C.A.</creator><general>Elsevier Inc</general><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9109-4812</orcidid></search><sort><creationdate>20220401</creationdate><title>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</title><author>Jones, K.A. ; Small, A.D. ; Ray, S. ; Hamilton, D.J. ; Martin, W. ; Robinson, J. ; Goodfield, N.E.R. ; Paterson, C.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Breast cancer</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Cancer therapies</topic><topic>Cardiology</topic><topic>Cardiotoxicity</topic><topic>diagnostic and prognostic application</topic><topic>dyssynchrony</topic><topic>Ejection fraction</topic><topic>Entropy</topic><topic>Female</topic><topic>Heart Diseases</topic><topic>Humans</topic><topic>image analysis</topic><topic>Imaging</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Original</topic><topic>Original Article</topic><topic>Radiology</topic><topic>Radionuclide Ventriculography</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>RNA: planar</topic><topic>Stroke Volume</topic><topic>Ventricular Dysfunction, Left - chemically induced</topic><topic>Ventricular Dysfunction, Left - diagnostic imaging</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, K.A.</creatorcontrib><creatorcontrib>Small, A.D.</creatorcontrib><creatorcontrib>Ray, S.</creatorcontrib><creatorcontrib>Hamilton, D.J.</creatorcontrib><creatorcontrib>Martin, W.</creatorcontrib><creatorcontrib>Robinson, J.</creatorcontrib><creatorcontrib>Goodfield, N.E.R.</creatorcontrib><creatorcontrib>Paterson, C.A.</creatorcontrib><collection>SpringerOpen (Open Access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of nuclear cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, K.A.</au><au>Small, A.D.</au><au>Ray, S.</au><au>Hamilton, D.J.</au><au>Martin, W.</au><au>Robinson, J.</au><au>Goodfield, N.E.R.</au><au>Paterson, C.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy</atitle><jtitle>Journal of nuclear cardiology</jtitle><stitle>J. Nucl. Cardiol</stitle><addtitle>J Nucl Cardiol</addtitle><date>2022-04-01</date><risdate>2022</risdate><volume>29</volume><issue>2</issue><spage>581</spage><epage>589</epage><pages>581-589</pages><issn>1071-3581</issn><eissn>1532-6551</eissn><abstract>Accurate diagnostic tools to identify patients at risk of cancer therapy-related cardiac dysfunction (CTRCD) are critical. For patients undergoing cardiotoxic cancer therapy, ejection fraction assessment using radionuclide ventriculography (RNVG) is commonly used for serial assessment of left ventricular (LV) function.
In this retrospective study, approximate entropy (ApEn), synchrony, entropy, and standard deviation from the phase histogram (phase SD) were investigated as potential early markers of LV dysfunction to predict CTRCD. These phase parameters were calculated from the baseline RNVG phase image for 177 breast cancer patients before commencing cardiotoxic therapy.
Of the 177 patients, 11 had a decline in left ventricular ejection fraction (LVEF) of over 10% to an LVEF below 50% after treatment had commenced. This patient group had a significantly higher ApEn at baseline to those who maintained a normal LVEF throughout treatment. Of the parameters investigated, ApEn was superior for predicting the risk of CTRCD. Combining ApEn with the baseline LVEF further improved the discrimination between the groups.
The results suggest that RNVG phase analysis using approximate entropy may aid in the detection of sub-clinical LV contraction abnormalities, not detectable by baseline LVEF measurement, predicting a subsequent decline in LVEF.</abstract><cop>Cham</cop><pub>Elsevier Inc</pub><pmid>32748278</pmid><doi>10.1007/s12350-020-02277-z</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9109-4812</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1071-3581 |
ispartof | Journal of nuclear cardiology, 2022-04, Vol.29 (2), p.581-589 |
issn | 1071-3581 1532-6551 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8993717 |
source | Springer Nature |
subjects | Breast cancer Breast Neoplasms - diagnostic imaging Breast Neoplasms - drug therapy Cancer therapies Cardiology Cardiotoxicity diagnostic and prognostic application dyssynchrony Ejection fraction Entropy Female Heart Diseases Humans image analysis Imaging Medical diagnosis Medicine Medicine & Public Health Nuclear Medicine Original Original Article Radiology Radionuclide Ventriculography Retrospective Studies Risk Assessment RNA: planar Stroke Volume Ventricular Dysfunction, Left - chemically induced Ventricular Dysfunction, Left - diagnostic imaging Ventricular Function, Left |
title | Radionuclide ventriculography phase analysis for risk stratification of patients undergoing cardiotoxic cancer therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T02%3A57%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radionuclide%20ventriculography%20phase%20analysis%20for%20risk%20stratification%20of%20patients%20undergoing%20cardiotoxic%20cancer%20therapy&rft.jtitle=Journal%20of%20nuclear%20cardiology&rft.au=Jones,%20K.A.&rft.date=2022-04-01&rft.volume=29&rft.issue=2&rft.spage=581&rft.epage=589&rft.pages=581-589&rft.issn=1071-3581&rft.eissn=1532-6551&rft_id=info:doi/10.1007/s12350-020-02277-z&rft_dat=%3Cproquest_pubme%3E2648552081%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c527t-6e3ac356d80c38dc67bde0c5e4dd787401b5cb05e5dc6c43e0d43a5566efced23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2648552081&rft_id=info:pmid/32748278&rfr_iscdi=true |